TAPI-1, known in the earlier literature as just TAPI, is an inhibitor of tumor necrosis factor-alpha converting enzyme (TACE)/ADAM 17, that inhibits the cleavage of TNF-α, TNFRI (p60), and TNFRII (p80). It was shown on mice model, that administration of TAPI-1 to mice with skin fibrosis induced by daily BLM injections lead to the significant suppressed BLM-induced skin thickness and the number of myofibroblasts, thus was suggested, that targeting the TNFalpha converting enzyme might be a new type of therapy for patients with systemic sclerosis (SSc).